Recon: Novartis licenses Arrowhead's neuromuscular drug for up to $2B; Paul Offit removed from FDA’s VRBPAC

• RFK Jr. critic Paul Offit dismissed from FDA's vaccine advisory committee (Endpoints) (Pink Sheet)
• The key health care policies at stake in Congress’ government funding fight (STAT)
• Trump says CDC is ‘being ripped apart’ over Covid products, calls for drugmakers to prove their benefits (STAT)
• Exclusive: Kennedy's autism data project draws more than 100 research proposals (Reuters)
• Arrowhead, Novartis in up to $2 billion deal for neuromuscular therapy license (Reuters)
• Sanofi's Wayrilz snags FDA endorsement in ITP (Fierce Phama)
• Eisai scores FDA nod for subcutaneous Leqembi maintenance dose (Fierce Pharma)

• Chinese companies turn to generics as shipments behind US weight-loss craze fade (Reuters)
• CapVest snaps up German generics maker Stada (Fierce Pharma)
• Which Countries Have Adopted International Regulatory Alignment Documents? (MedTech Insight)
• Sweden’s Sectra Expands Global Digital Pathology And AI Footprint (MedTech Insight)
• Swissmedic Slashes Months Off Review Time For Certain Drug Filings (Pink Sheet)
• How England’s Cancer Vaccine Launch Pad Helped Scancell Speed Up Trial Patient Recruitment (Pink Sheet)

• Ionis drug lowers triglycerides, reduces pancreas damage in late-stage studies (STAT)
• United Therapeutics shares hit record high after late-stage win for lung disease drug (Reuters)
• Cytokinetics' drug more effective for heart disease symptoms than standard-of-care (Reuters)
• Make statins available without a prescription (STAT)
• Biotech veterans John Maraganore, Clive Meanwell launch new heart disease startup with lofty goals (STAT)
• Merck's cholesterol drug gets a boost with another late-stage trial success (Reuters)
• Zymeworks halts development of cancer drug after trial setback (Reuters)
• Nvidia-backed Charm Therapeutics gets $80M to take AI-designed cancer drug to clinic (Endpoints)
• Upstream Bio's Phase 2 win could set it up as a potential Dupixent, Tezspire competitor (Endpoints)
• Exclusive: Neon Health raises $6M for AI to help patients access specialty drugs (Endpoints)
• Merck, Bayer's Verquvo posts perplexing trial fail (Fierce Pharma)
• Novo Backed by Key Danish Investor as Drugmaker Seeks Revival (Bloomberg)

• As reports of ‘AI psychosis’ spread, clinicians scramble to understand how chatbots can spark delusions (STAT)
• AI devices with no clinical validation tied to more recalls, study finds (MedTech Dive)
• European Commission Review of the MDR and IVDR – Where Are We Right Now? (MedTech Insight)
• Outdated SME Thresholds Need EU Review, Say German Medtechs (MedTech Insight)

• Women and Older Adults are Driving Sales of Creatine Higher (Bloomberg)
• Kraft Heinz to Separate Into Two Publicly Traded Companies (Bloomberg)

• U.S. science and universities are becoming political hostages in the Orbánization of knowledge (STAT)
• Trump administration restored funding for major diabetes study. The pause still set researchers back (STAT)
• Appellate court rules Trump’s global tariffs illegal, but delays action (MedTech Dive)